Syn-Bio in CRISPR is still 20+ years away – there are no successes to date
Jo Zayner, 23, (Jo Zayner, Dr. Jo Zayner is a visionary biochemist and genetic designer. For over 15 years, they have pioneered work in the field of bioengineering, publishing a number of scientific papers on the topic. Jo received their PhD in Biophysics from the University of Chicago, winning several awards for their work on engineering proteins. They then spearheaded work on developing engineered microbes for Mars terraforming at NASA, eventually leaving to start The ODIN, a bioengineering company based in Austin, Texas that is working to make genetic engineering accessible to everyone. Zayner’s groundbreaking work in human genetic engineering and medicine has been the focus of many documentaries, including the Netflix documentary Unnatural Selection and the NYT documentary Gut Hack. They have been made fun of on Last Week Tonight with John Oliver and written about in media all over the world including The New York Times, The New Yorker, El País, Le Monde, Time, Scientific American and NPR, among others., Phd, 1-2-2023, The death of SynthBio companies and my other predictions for Biotech in 2023, https://amateurgods.substack.com/p/the-death-of-synthbio-companies-and, 6-30-2023) SCade
The difficult realities of in vivo CRISPR gene editing therapies set in and funding slows. CRISPR’s use in human cells has been going on for about a decade. And while we have been promised the world, the only real success CRISPR has had in therapeutics is with ex vivo editing. Taking patient cells and editing them outside the body and putting them back in. So called CAR-T cell therapy is the most well-known example of this. While there have been a number of attempts at in vivo editing, using CRISPR gene editing on cells inside a patient’s body, none have really worked out. To date, the best success has been a therapy for ATTR amyloidosis but even then the treatment doesn’t actually prevent progression of the disease despite gene editing successfully. This therapy had high hopes because it was a liver target and therapies tend to accumulate in the liver, giving them a higher likelihood of success. The other low hanging fruit is eye therapies because of the immune privileged nature of the eye. One of the three FDA approved non-CRISPR gene therapies targets the eye, Luxturna. CRISPR clinical trials for eye disease have not progressed, implying that results have been very limited. I’m not saying we will never see in vivo CRISPR therapies. Look at RNA, it took 20ish years to mature into an FDA approved medicine. From the outlook right now I imagine in vivo CRISPR therapies are on the same track.